JP2022522979A - スクリーニング方法 - Google Patents
スクリーニング方法 Download PDFInfo
- Publication number
- JP2022522979A JP2022522979A JP2021541204A JP2021541204A JP2022522979A JP 2022522979 A JP2022522979 A JP 2022522979A JP 2021541204 A JP2021541204 A JP 2021541204A JP 2021541204 A JP2021541204 A JP 2021541204A JP 2022522979 A JP2022522979 A JP 2022522979A
- Authority
- JP
- Japan
- Prior art keywords
- chr7
- dna
- methylation
- neoplasm
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 245
- 238000012216 screening Methods 0.000 title claims abstract description 39
- 230000011987 methylation Effects 0.000 claims abstract description 182
- 238000007069 methylation reaction Methods 0.000 claims abstract description 182
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 141
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 50
- 239000012472 biological sample Substances 0.000 claims abstract description 49
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 46
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 33
- 206010061968 Gastric neoplasm Diseases 0.000 claims abstract description 22
- 208000025402 neoplasm of esophagus Diseases 0.000 claims abstract description 22
- 238000012544 monitoring process Methods 0.000 claims abstract description 19
- 206010061882 Oesophageal neoplasm Diseases 0.000 claims abstract description 15
- 108020004414 DNA Proteins 0.000 claims description 189
- 239000000523 sample Substances 0.000 claims description 160
- 108090000623 proteins and genes Proteins 0.000 claims description 108
- 230000014509 gene expression Effects 0.000 claims description 66
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims description 61
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims description 59
- 201000011510 cancer Diseases 0.000 claims description 59
- 210000001519 tissue Anatomy 0.000 claims description 59
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 claims description 56
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 claims description 56
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 56
- 230000001613 neoplastic effect Effects 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 210000003238 esophagus Anatomy 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 230000007067 DNA methylation Effects 0.000 claims description 26
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 25
- 208000009956 adenocarcinoma Diseases 0.000 claims description 23
- 208000003200 Adenoma Diseases 0.000 claims description 18
- 230000003211 malignant effect Effects 0.000 claims description 18
- 210000002381 plasma Anatomy 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 17
- 210000001808 exosome Anatomy 0.000 claims description 17
- 238000001574 biopsy Methods 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 230000002759 chromosomal effect Effects 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 206010001233 Adenoma benign Diseases 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 238000002052 colonoscopy Methods 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 4
- 230000009826 neoplastic cell growth Effects 0.000 abstract description 22
- 230000002496 gastric effect Effects 0.000 abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 description 154
- 102000039446 nucleic acids Human genes 0.000 description 150
- 108020004707 nucleic acids Proteins 0.000 description 150
- 239000013615 primer Substances 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 65
- 230000003321 amplification Effects 0.000 description 62
- 238000003199 nucleic acid amplification method Methods 0.000 description 62
- 238000009396 hybridization Methods 0.000 description 58
- 125000003729 nucleotide group Chemical group 0.000 description 53
- 239000002773 nucleotide Substances 0.000 description 48
- 210000002784 stomach Anatomy 0.000 description 48
- 238000003752 polymerase chain reaction Methods 0.000 description 47
- 238000012360 testing method Methods 0.000 description 40
- 238000003556 assay Methods 0.000 description 39
- 238000001514 detection method Methods 0.000 description 36
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 34
- 239000003550 marker Substances 0.000 description 31
- 108091008146 restriction endonucleases Proteins 0.000 description 29
- 239000002987 primer (paints) Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000012634 fragment Substances 0.000 description 25
- 230000008569 process Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 22
- 238000002820 assay format Methods 0.000 description 21
- 108091029430 CpG site Proteins 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 19
- 239000002253 acid Substances 0.000 description 19
- 201000004101 esophageal cancer Diseases 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 18
- 150000007513 acids Chemical class 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 206010017758 gastric cancer Diseases 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- 230000009471 action Effects 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 229940104302 cytosine Drugs 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 210000005170 neoplastic cell Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002703 mutagenesis Methods 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 206010058314 Dysplasia Diseases 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108091093037 Peptide nucleic acid Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 210000001156 gastric mucosa Anatomy 0.000 description 9
- 238000007834 ligase chain reaction Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 108010042407 Endonucleases Proteins 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 8
- 210000002318 cardia Anatomy 0.000 description 8
- 239000013068 control sample Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108010077544 Chromatin Proteins 0.000 description 7
- 102100031780 Endonuclease Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 210000003483 chromatin Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229940035893 uracil Drugs 0.000 description 7
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 108060004795 Methyltransferase Proteins 0.000 description 6
- 102000016397 Methyltransferase Human genes 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001839 endoscopy Methods 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 230000006607 hypermethylation Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 210000001187 pylorus Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 5
- 108091029523 CpG island Proteins 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 5
- 229940079826 hydrogen sulfite Drugs 0.000 description 5
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000005070 sphincter Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 229910052788 barium Inorganic materials 0.000 description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 210000003236 esophagogastric junction Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007855 methylation-specific PCR Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 208000023514 Barrett esophagus Diseases 0.000 description 3
- 208000023665 Barrett oesophagus Diseases 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 239000001177 diphosphate Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000012175 pyrosequencing Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 description 2
- 206010060850 Gastric adenoma Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 241001424413 Lucia Species 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 101710111879 Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- MGPYJVWEJNTXLC-UHFFFAOYSA-N [6-[6-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyhexylcarbamoyl]-6'-(2,2-dimethylpropanoyloxy)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] 2,2-dimethylpropanoate Chemical compound C12=CC=C(OC(=O)C(C)(C)C)C=C2OC2=CC(OC(=O)C(C)(C)C)=CC=C2C11OC(=O)C2=CC=C(C(=O)NCCCCCCOP(N(C(C)C)C(C)C)OCCC#N)C=C21 MGPYJVWEJNTXLC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- -1 bisulfite Chemical class 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 102100032270 tRNA (cytosine(38)-C(5))-methyltransferase Human genes 0.000 description 2
- 101710184308 tRNA (cytosine(38)-C(5))-methyltransferase Proteins 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000001942 upper esophageal sphincter Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710105312 Branched-chain-amino-acid aminotransferase Proteins 0.000 description 1
- 101710097328 Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 description 1
- 101710194298 Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108091062167 DNA cytosine Proteins 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 206010050161 Gastric dysplasia Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 101150016712 IKZF1 gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 206010050171 Oesophageal dysplasia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710158343 Probable branched-chain-amino-acid aminotransferase Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 101710199693 Putative branched-chain-amino-acid aminotransferase Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 101150016587 bcat-1 gene Proteins 0.000 description 1
- AZPBDRUPTRGILK-UHFFFAOYSA-N benzotriazol-1-ium-1-ylidenemethanediamine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2N(C(=N)N)N=NC2=C1 AZPBDRUPTRGILK-UHFFFAOYSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000024334 diffuse gastric cancer Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000009558 endoscopic ultrasound Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 1
- 208000024331 hereditary diffuse gastric cancer Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000005125 simple columnar epithelium Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 210000000470 submucous plexus Anatomy 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000000504 visceral peritoneum Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378 ...50472798;
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1;及び/又は(2)IKZF1の2kb上流を含む遺伝子領域から選択されるDNA領域のメチル化状態を評価することを含む方法であって、対照レベルと比較して、グループ(i)及び/又は(ii)のDNA領域の少なくとも1つのメチル化のより高いレベルが食道もしく胃の新生物又は食道もしくは胃の腫瘍性状態の発症の素因を示す。
(1)BCAT1サブ領域chrl2:25101992-25102093(配列番号1又は対応するマイナス鎖)及びchrl2:25101909-25101995(配列番号2又は対応するマイナス鎖);及び
(2)IKZF1サブ領域:chr7:50343867-50343961(配列番号3又は対応するマイナス鎖)及びchr7:50343804-5033895(配列番号4又は対応するマイナス鎖)
(1)配列番号1又は配列番号2又は対応するマイナス鎖によって定義されるBCAT1サブ領域及び
(2)配列番号3又は配列番号4又は対応するマイナス鎖によって定義されるIKZF1サブ領域。
chr7:50343869 chr7:50343872 chr7:50343883
chr7:50343889 chr7:50343890 chr7:50343897
chr7:50343907 chr7:50343909 chr7:50343914
chr7:50343934 chr7:50343939 chr7:50343950
chr7:50343959 chr7:50343805 chr7:50343822
chr7:50343824 chr7:50343826 chr7:50343829
chr7:50343831 chr7:50343833 chr7:50343838
chr7:50343847 chr7:50343850 chr7:50343858
chr7:50343864 chr7:50343869 chr7:50343872
chr7:50343890
又は反対側のDNA鎖の位置n+1にある対応するシトシンの中の1つ又は複数のメチル化を評価することができる。
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378 ...50472798;
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1;及び/又は(2)IKZF1の2kb上流を含む遺伝子領域から選択されるDNA領域の発現レベルを評価することを含む方法であって、対照レベルと比較して、グループ(i)及び/又は(ii)のDNA領域の少なくとも1つの発現のより低いレベルが食道又は胃の新生物もしくは腫瘍性状態の発症の素因を示す。
;又は
の複数を含み、
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378...50472798
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1及び又は(2)IKZF1のいずれか2つ以上の2kb上流を含む遺伝子領域:
から選択されるDNA領域のメチル化状態を評価することを含む方法であって、メチル化レベルが対照レベルよりも高いとき、対照レベルと比較してグループ(i)及び/又は(ii)のDNA領域の少なくとも1つのメチル化のより高いレベルが、食道もしくは胃の新生物又は食道もしくは胃の新生物の発症の素因を示し、及び任意選択で、結腸内視鏡検査、悪性組織の外科的除去、及び/又は放射線、化学療法、もしくは免疫療法を受けるように前記個体に提供するか、ガイドするか又は助言する。
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378...50472798
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1及び又は(2)IKZF1の2kb上流を含む遺伝子領域:
から選択されるDNA領域の発現レベルを評価することを含む方法であって、
メチル化レベルが対照レベルよりも低いとき、対照レベルと比較してグループ(i)及び/又は(ii)のDNA領域の少なくとも1つの発現のより低いレベルが、食道又は胃の新生物もしくは新生物の発症の素因を示し、及び任意選択で、結腸鏡検査、悪性組織の外科的除去、及び/又は放射線、化学療法、もしくは免疫療法を受けるように前記個体に示すか、ガイドするか又は助言する。
(1)BCAT1サブ領域chrl2:25101992-25102093(配列番号11又は対応するマイナス鎖)及びchrl2:25101909-25101995(配列番号16又は対応するマイナス鎖)
(2)IKZF1サブ領域:chr7:50343867-50343961(配列番号2又は対応するマイナス鎖)及びchr7:50343804-5033895(配列番号24又は対応するマイナス鎖)
から選択される1つ又は複数の染色体サブ領域で評価される、前記1に記載の方法。
(IKZF1)
chr7:50343869 chr7:50343872 chr7:50343883
chr7:50343889 chr7:50343890 chr7:50343897
chr7:50343907 chr7:50343909 chr7:50343914
chr7:50343934 chr7:50343939 chr7:50343950
chr7:50343959 chr7:50343805 chr7:50343822
chr7:50343824 chr7:50343826 chr7:50343829
chr7:50343831 chr7:50343833 chr7:50343838
chr7:50343847 chr7:50343850 chr7:50343858
chr7:50343864 chr7:50343869 chr7:50343872
chr7:50343890
又は反対側のDNA鎖の位置n+1にある対応するシトシン
から選択される1つ又は複数のシトシン残基のメチル化を評価することを含む前記20に記載の方法。
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378...50472798;
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1:及び/又は(2)IKZF1
の2kb上流を含む遺伝子領域
から選択されるDNA領域のメチル化状態を評価することを含む方法であって、
対照レベルと比較して、グループ(i)及び/又は(ii)のDNA領域の少なくとも1つのメチル化のより高いレベルが食道もしくは胃の新生物又は食道もしくは胃の腫瘍性状態の発症の素因を示す。
chr7:50343869 chr7:50343872 chr7:50343883
chr7:50343889 chr7:50343890 chr7:50343897
chr7:50343907 chr7:50343909 chr7:50343914
chr7:50343934 chr7:50343939 chr7:50343950
chr7:50343959 chr7:50343805 chr7:50343822
chr7:50343824 chr7:50343826 chr7:50343829
chr7:50343831 chr7:50343833 chr7:50343838
chr7:50343847 chr7:50343850 chr7:50343858
chr7:50343864 chr7:50343869 chr7:50343872
chr7:50343890
または反対側のDNA鎖の位置n+1にある対応するシトシンである。
(a)プローブもしくはプライマーの設計及び/又は製造
(b)DNAのメチル化感受性エンドヌクレアーゼ消化
ハイブリダイゼーションアッセイフォーマット
増幅アッセイフォーマット
(c)その他のアッセイフォーマット
(d)非メチル化DNAの選択的突然変異誘発
シークエンスベースの検出
制限エンドヌクレアーゼベースのアッセイフォーマット
陽性の読み出しアッセイフォーマット
含むプロセスを使用して決定される。
ハイブリダイゼーションベースのアッセイフォーマット
増幅ベースのアッセイフォーマット
を含むプロセスを実行することによって検出される。
陰性読み出しアッセイ
を含むプロセスを使用して決定される。
ハイブリダイゼーションベースのアッセイフォーマット
増幅ベースのアッセイフォーマット
を含むプロセスを実行することによって検出される。
によって定義される、転写開始部位の2kb上流を含む領域:
から選択されるDNA領域の発現レベルを評価することを含む方法であって、
(i)インビボ検出
(ii)蛍光原位置(in situ)による細胞内のRNA発現のダウンレギュレーションの検出
(iii)例えばアレイ技術によるRNAの発現プロフィールの評価(Alonら、Proc.Natl.Acad.Sci.USA:96:6745-6750,June 1999)。
(iv)例えば、免疫学的検定法による細胞抽出物中の変化した腫瘍性マーカータンパク質レベルの測定。
(v)例えば、免疫組織化学による、細胞表面上のタンパク質腫瘍性マーカーの変化した発現の決定。
(vi)前記のポイント(iv)および(v)に詳述されているものに加えて、適切な機能テスト、酵素テスト、又は免疫学的テストに基づく、変化したタンパク質発現の決定。
の複数を含むアレイであって、
研究コホート
方法
結果
組織
血液
結論
表1:研究コホート
表2:早期癌と末期癌の血液陽性数
前立腺癌は、ステージに分類されなかった。
実施例2:胃がんの分析
癌及び非癌組織標本におけるBCAT1及びIKZF1のメチル化
表3
血液サンプル中のBCAT1及びIKZF1のメチル化
少なくとも3.9mlのすべての血漿サンプルは、メチル化されたBCAT1及びIKZF1DNAの存在について、Clinical Genomics Technologiesで分析された。Pedersen S,Symonds E,Baker Rらに記載されているように、サンプルは22サンプルと2つの対照プロセスのバッチで処理および分析された。(結腸直腸腫瘍の検出のための血漿中のメチル化BCAT1及びIKZF1の分析の評価。BMCCancer 2015:15:654)。ただし、次の変更がされた。亜硫酸水素塩変換のセットアップとその後の精製は、QIAcube HT機器(Qiagen,Hilden,Germany)で自動化され、メチル化特異的PCRアッセイのIKZF1成分は、部分的にメチル化されたIKZF1標的領域(表5)の検出を可能にするように修飾された。各血漿サンプルから亜硫酸水素塩変換されたDNAは、Light Cycler 480II機器(Roche Diagnostics,IN,USA)で実行されたリアルタイムPCRで3回分析された。少なくとも1つのPCR複製がBCAT1又はIKZF1DNAメチル化のどちらか一方に対して陽性であった場合、サンプルは定性的に陽性とみなされた。
主な結果指標は、診断による陽性率であった。95%信頼区間(95%CI)の計算では、二項分布が仮定された。対である陽性率と一致分析の違いはマクネマー検定を使用して分析されたが、対になっていない比率の違いはχ2検定を使用した(両側;有意水準、0.05)。潜在的な交絡共変数(年齢、性別)は、多重ロジスティック回帰分析によって分析された。テスト感度の推定値は、真陽性と偽陰性の合計に対する真陽性の比率として表された。特異性は、CRCがない場合の1-陽性率として推定された。糞便免疫化学検査(FIT)は定量的であり、陽性のカットオフを変えることができるので、受信者動作特性曲線分析を実施し、血液DNA試験と同等の特異度で相対的な真陽性率(したがって感度)を推定することにより、試験結果の比較が容易になった。前記の統計分析には、GraphPadオンライン科学ソフトウェアツールを使用した。0.05未満のP値は統計的に有意であるとみなされた。
プライマーとプローブ
gtcttcctgc tgatgcaatc cgctaggtcg cgagtctccg ccgcgagagg gccggtctgc aatccagccc gccacgtgta ctcgccgccg cctcgggcac tg(配列番号1)
gacgacgcac cctctccgtg tcccgctctg cgcccttctg cgcgccccgc tccctgtacc ggagcagcga tccgggaggc ggccgagagg tgcgc(配列番号2)
検体のIKZF1及びBCAT1を横切るメチル化レベルを測定するために使用されるPCRプロトコル
表5:リアルタイムPCRプロトコルBCAT1およびIKZF1
実施例4:エクソソームサンプルについての分析
表7:メチル化BCAT1およびIKZF1のエクソソーム陽性
文献目録
Abrams and Stanton, Methods Enzymol., 212:71-74, 1992
Adorjan et al. Nucl. Acids Res., 30: e21, 2002
Alon et al, Proc. Natl. Acad. Sci. USA: 96:6745-6750, June 1999
Ammerpohl et al. Biochim Biophys Acta. 1790:847-62, 2009
Beaucage, et al. Tetrahedron Letters 22:1859-1862, 1981
Bianco et al., Hum. Mutat., 14:289-293, 1999
Bonner and Laskey, Eur. J. Biochem. 46:83, 1974
Bresslauer et al., Proc. Natl. Acad. Sci. USA, 83: 3746-3750, 1986
Caruthers, M. H., et al, Methods in Enzymology, Vol. 154, pp. 287-314 (1988)
Chen and Kwok, Nucleic Acids Res. 25:347-353, 1997
Clark et al. Nat Protoc. 1:2353-64, 2006
Clark et al., Nucl. Acids Res. 22:2990-2997, 1994
Cottrell et al., Nucl. Acids Res. 32: elO, 2003
DeGraves, et al., Biotechniques 34(1):106-10, 112-5 (2003)
Deiman B, et al., Mol. Biotechnol. 20(2): 163-79 (2002)
Deng et al. Chin. J. Cancer Res., 12:171-191, 2000
Dieffenbach (ed) and Dveksler (ed) (In: PCR Primer: A Laboratory Manual, Cold Spring Harbour Laboratories, NY, 1995
Eads et al, Nucl. Acids Res. 28: E32, 2000
Egholm et al., Am. Chem. Soc., 114:1895, 1992
Egholm et al, Nature, 365:566, 1993
Fodor et al, Science 767-773, 1991
Frommer et al., Proc. Natl. Acad. Sci. USA 89:1827-1831 (1992)
Gibson et al., Genome Research 6:995-1001 (1996)
Golub et al., Science, 286:531-537, 1999
Gonzalgo & Jones, Nucleic Acids Res. 25:2529-2531 (1997)
Gonzalgo et al., Cancer Res. 57:594-599, 1997
Gregory and Feil, Nucleic Acids Res., 27, e32i-e32iv, 1999
Havelange et al., Blood 2011, 118:2827
Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826 (1996)
Holland et al., Proc. Natl. Acad. Sci. USA, 88:7276-7280, 1991
Javierre et al., Mol. Cancer Res. 9(8): 1139-51, 2011
Kawai et al. , Mol. Cell. Biol. 14:7421-7427, 1994
Kibriya et al., BMC 2011, 4:50
Kristensen and Hansen Clin Chem. 55:1471-83, 2009
Kuppuswamy et al, Proc. Natl. Acad. Sci. USA 88:1143-1147, 1991
Landegren et al., Genome Res., 8(8): 769-776, 1998
Lee et al., Nucleic Acid Res. 21:3761-3766, 1993
Markowitz and Bertagnolli, 2009, N. Engl. J. Med. 361(25): 2449-60
Marmur and Doty, J. Mol. Biol. 5:109, 1962
Martinez et al., Am. J. Surg Pathol. 2012, 36:296
McPherson et al, PCR: A Practical Approach (series eds, D. Rickwood and B. D. Hames),
IRL Press Limited, Oxford pp 1-253, 1991
Messing, Methods Enzymol, 101, 20-78, 1983
Mhlanga and Malmberg, Methods 25:463-471, 2001
Moore et al., BBA, 1402:239-249, 1988
Narang, et al. Meth. Enzymol 68: 90, 1979
Nevrivy et al. JBC 2000, 275(22): 16827-36
Nielsen et al. J. Chem. Soc. Perkin Trans., 1:3423, 1997
Olek, et al. Nat. Genet. 17(3): 275-6 (1997)
Orum et al., Clin. Chem. 45:1898-1905, 1999
Orum et al, Nucl. Acids Res., 21:5332, 1993
Oster et al., Int. J. Cancer 2011, 129:2855
Pathak et al. PLoS One 2011, 6:e22628
Rand et al. Epigenetics 1:94-100, 2006
Rand et al. Nucl. Acids Res. 33:el27, 2005
Rein, et al. Nucleic Acids Res. 26 (10): 2255-64 (1998)
Sadri & Hornsby, Nucl. Acids Res. 24:5058-5059 (1996)
Sambrook et al, Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989)
Santa Lucia, Proc. Natl. Acad. Sci. USA, 95: 1460-1465, 1995
Shames et al. Cancer Lett. 251:187-98, 2007
Simeonov and Nikiforov, Nucleic Acids Research, 30(17): 1-5, 2002
Singer-Sam et al., Nucl. Acids Res. 18:687, 1990
Singer-Sam et al., PCR Methods Appl. 1: 160-163, 1992
Singh and Wengel, Chem. Commun. 1247, 1998
Slattery et al., Carcinogenesis 2011, 32:160
Southern et al., Genomics, 13:1008-1017, 1992
Szabo and Mann, Genes Dev. 9: 3097-3108, 1995
Toyota et al, Cancer Res. 59:2307-12 (1999)
Uhlmann et al., Electrophoresis, 23:4072-4079, 2002
Wedemeyer et al., Clinical Chemistry 48:9 1398-1405, 2002
Weissleder et al, Nature Medicine 6:351-355, 2000
Weitzel JN (December 1999), Cancer 86 (11 Suppl): 2483-92
Worm et al., Clin. Chem., 47:1183-1189, 2001
Xiong & Laird, Nucleic Acids Res. 25:2532-2534 (1997)
Yamashita et al. (Cancer Sci. 2010, 101:1708)
Zyskind et al, Recombinant DNA Laboratory Manual, (Acad. Press, 1988)
Claims (23)
- 個体の食道又は胃の新生物の発症もしくは発症の素因をスクリーニングする方法又は個体の食道もしく胃の新生物をモニタリングする方法であって、前記方法は、前記個体の生物学的サンプルにおいて、
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378...50472798
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1及び又は(2)IKZF1のいずれか2つ以上の2kb上流を含む遺伝子領域:
から選択されるDNA領域のメチル化状態を評価することを含む方法であって、メチル化レベルが対照レベルよりも高いとき、対照レベルと比較してグループ(i)及び/又は(ii)のDNA領域の少なくとも1つのより高いレベルのメチル化が、食道もしくは胃の新生物または食道もしくは胃の新生物の発症の素因を示し、及び任意選択で、結腸鏡検査、悪性組織の外科的除去、及び/又は放射線、化学療法、又は免疫療法を受けるように前記個体に示すか、ガイドするか又は助言する。 - 個体の食道又は胃の新生物の発症もしくは発症の素因をスクリーニングする方法又は個体の食道もしく胃の新生物をモニタリングする方法であって、前記方法は、前記個体の生物学的サンプルにおいて、
(i)Hg19座標
(1)chrl2:24962958..25102393;及び/又は
(2)chr7:50344378...50472798
によって定義される、転写開始部位の2kb上流を含む領域:又は
(ii)(1)BCAT1及び又は(2)IKZF1の2kb上流を含む遺伝子領域:
から選択されるDNA領域の発現レベルを評価することを含む方法であって、
メチル化レベルが対照レベルよりも低いとき、対照レベルと比較してグループ(i)及び/又は(ii)のDNA領域の少なくとも1つのより低いレベルの発現が、食道または胃の新生物もしくは新生物の発症の素因を示し、及び任意選択で、結腸鏡検査、悪性組織の外科的除去、及び/又は放射線、化学療法、又は免疫療法を受けるように前記個体に示すか、ガイドするか又は助言する。 - 前記方法が、前記生物学的サンプル中のBCAT1又はIKZF1のどちらか一方をスクリーニングすることを対象とする請求項1または2に記載の方法。
- 前記方法が、前記生物学的サンプル中のBCAT1又はIKZF1の両方をスクリーニングすることを対象とする請求項1または2に記載の方法。
- 前記BCAT1及びIKZF1のうちの一方のみが、調節されたメチル化又は発現を示す請求項4に記載の方法。
- 前記BCAT1及びIKZF1の両方が、調節されたメチル化又は発現を示す請求項4に記載の方法。
- 新生物が悪性である請求項1から6のいずれか1項に記載の方法。
- 前記悪性新生物が腺癌である請求項7に記載の方法。
- 前記新生物が悪性ではない請求項1から6のいずれか1項に記載の方法。
- 前記非悪性新生物が腺腫である請求項9に記載の方法。
- 前記対照レベルが非腫瘍性レベルである請求項1から10のいずれか1項に記載の方法。
- 前記対照レベルが、前記個体から以前にスクリーニングされた生物学的サンプルのレベルである請求項1から10のいずれか1項に記載の方法。
- 前記対照レベルと比較したメチル化のレベルの減少、または前記対照レベルと比較したDNA発現のレベルの増加が、新生物の除去を示す請求項12に記載の方法。
- 前記新生物が胃の新生物である請求項1から13のいずれか1項に記載の方法。
- 前記新生物が食道の新生物である請求項1から13のいずれか1項に記載の方法。
- 前記生物学的サンプルが、外科的切除、組織生検、唾液、尿又は血液サンプルである請求項1から15のいずれか1項に記載の方法。
- 前記血液サンプルが、全血、血清、血漿、エクソソーム、又はバフィーコートである請求項16に記載の方法。
- DNAメチル化スクリーニングが無細胞DNAを対象とする請求項17に記載の方法。
- 前記無細胞DNAが循環腫瘍DNAである請求項18に記載の方法。
- 前記メチル化が、
(1)BCAT1サブ領域chrl2:25101992-25102093(配列番号9又は対応するマイナス鎖)及びchrl2:25101909-25101995(配列番号16又は対応するマイナス鎖);
(2)IKZF1サブ領域:chr7:50343867-50343961(配列番号2又は対応するマイナス鎖)及びchr7:50343804-5033895(配列番号24又は対応するマイナス鎖):
から選択される1つまたは複数の染色体サブ領域で評価される、請求項1に記載の方法。 - 前記方法は、
chr7:50343869 chr7:50343872 chr7:50343883
chr7:50343889 chr7:50343890 chr7:50343897
chr7:50343907 chr7:50343909 chr7:50343914
chr7:50343934 chr7:50343939 chr7:50343950
chr7:50343959 chr7:50343805 chr7:50343822
chr7:50343824 chr7:50343826 chr7:50343829
chr7:50343831 chr7:50343833 chr7:50343838
chr7:50343847 chr7:50343850 chr7:50343858
chr7:50343864 chr7:50343869 chr7:50343872
chr7:50343890
又は反対側のDNA鎖の位置n+1にある対応するシトシン
から選択される1つ又は複数のシトシン残基のメチル化を評価することを含む請求項20に記載の方法。 - 前記発現レベルが、mRNA発現又はタンパク質発現である請求項2に記載の方法。
- 前記哺乳動物がヒトである請求項1から22のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019200359 | 2019-01-18 | ||
AU2019200359A AU2019200359A1 (en) | 2019-01-18 | 2019-01-18 | Screening method |
PCT/US2020/013623 WO2020150311A1 (en) | 2019-01-18 | 2020-01-15 | Screening method |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022522979A true JP2022522979A (ja) | 2022-04-21 |
Family
ID=71613603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021541204A Pending JP2022522979A (ja) | 2019-01-18 | 2020-01-15 | スクリーニング方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3911764A4 (ja) |
JP (1) | JP2022522979A (ja) |
CN (1) | CN113614248A (ja) |
AU (2) | AU2019200359A1 (ja) |
WO (1) | WO2020150311A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230154009A (ko) * | 2021-02-26 | 2023-11-07 | 온크그노스틱스 게엠베하 | 두경부 암의 진단 및 위험 평가 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140274748A1 (en) * | 2013-03-14 | 2014-09-18 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
JP2015515862A (ja) * | 2012-05-11 | 2015-06-04 | クリニカル ジェノミクス ピーティーワイ リミテッド | 結腸直腸がんのための診断用遺伝子マーカーパネル |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101284014B1 (ko) * | 2010-11-24 | 2013-07-09 | (주)지노믹트리 | 위암 진단을 위한 위암 특이적 메틸화 바이오마커 |
US11078539B2 (en) * | 2014-03-31 | 2021-08-03 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasm |
US10030272B2 (en) * | 2015-02-27 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Detecting gastrointestinal neoplasms |
JP6871926B2 (ja) * | 2015-08-31 | 2021-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチMayo Foundation for Medical Education and Research | 胃の新生物を検出すること |
-
2019
- 2019-01-18 AU AU2019200359A patent/AU2019200359A1/en not_active Abandoned
-
2020
- 2020-01-15 CN CN202080022890.XA patent/CN113614248A/zh active Pending
- 2020-01-15 AU AU2020209763A patent/AU2020209763A1/en active Pending
- 2020-01-15 JP JP2021541204A patent/JP2022522979A/ja active Pending
- 2020-01-15 WO PCT/US2020/013623 patent/WO2020150311A1/en unknown
- 2020-01-15 EP EP20741175.2A patent/EP3911764A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015515862A (ja) * | 2012-05-11 | 2015-06-04 | クリニカル ジェノミクス ピーティーワイ リミテッド | 結腸直腸がんのための診断用遺伝子マーカーパネル |
US20140274748A1 (en) * | 2013-03-14 | 2014-09-18 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
Non-Patent Citations (2)
Title |
---|
ERIN L SYMONDS ET AL., SPECIFICITY OF METHYLATED BCAT1 AND IKZF1 FOR COLORECTAL CANCER, JPN6022036313, ISSN: 0005039357 * |
ERIN L SYMONDS ET AL.: "Specificity of methylated BCAT1 and IKZF1 for colorectal cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.36, No.4_suppl, JPN6022036312, February 2018 (2018-02-01), ISSN: 0005039358 * |
Also Published As
Publication number | Publication date |
---|---|
EP3911764A1 (en) | 2021-11-24 |
WO2020150311A1 (en) | 2020-07-23 |
AU2020209763A1 (en) | 2021-08-05 |
CN113614248A (zh) | 2021-11-05 |
AU2019200359A1 (en) | 2020-09-10 |
EP3911764A4 (en) | 2022-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7035156B2 (ja) | 結腸直腸がんのエピジェネティックマーカー及び該マーカーを使用する診断法 | |
US20220213559A1 (en) | Diagnostic gene marker panel for colorectal cancer | |
JP6085603B2 (ja) | 結腸直腸がん及び乳がん診断法におけるdnaメチル化 | |
JP2022522979A (ja) | スクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210917 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230113 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230418 |